Transmucosal drug delivery device and method including chemical permeation enhancers

Patent metadata

Field	Value
Publication number	US-10632294-B2
Application number	US-201414537585-A
Country	US
Kind code	B2
Filing date	Nov 10, 2014
Priority date	Oct 8, 2009
Publication date	Apr 28, 2020
Grant date	Apr 28, 2020

Abstract

Devices and methods are provided for transmucosal drug delivery. The transmucosal drug delivery device may include a housing configured for intralumenal deployment, such as intravaginally, into a human or animal subject; a drug-dispensing portion which contains at least one drug, the drug-dispensing portion being configured to dispense the drug from the housing by positive displacement; and a permeability enhancer-dispensing portion configured to release or generate a permeability enhancing substance to disrupt at least one region of a mucosal barrier adjacent to the housing at a selected time while intralumenally deployed in the human or animal subject. The device may be operable to dispense the drug from the housing to a region of the mucosal barrier disrupted by the permeability enhancing substance.

First claim

We claim:

1. An intralumenal device for transmucosal drug delivery comprising:
a housing shaped and dimensioned for intralumenal deployment into, retention in, and removal from a lumen of a human or animal subject;
a drug-dispensing portion which contains at least one drug and comprises an actuator, the actuator being configured to dispense the at least one drug from the housing by positive displacement;
a permeability enhancer-dispensing portion configured to at least one of release and generate a permeability enhancing substance to disrupt at least one region of a mucosal barrier of the lumen adjacent to the housing by inhibiting enzyme activity or rendering the mucosal barrier more permeable to the at least one drug at a selected time while intralumenally deployed and retained in the lumen of the human or animal subject; and
a control module contained in the housing, the control module controlling the release or generation of the permeability enhancing substance and the dispensing of the at least one drug by activation of the actuator;
wherein the device is operable to dispense the at least one drug from the housing to the at least one region of the mucosal barrier disrupted by the permeability enhancing substance.

2. The device of claim 1 , wherein the lumen of the subject is selected from the group consisting of vagina, cervix, uterus, bladder, and rectum.

3. The device of claim 1 , wherein the device is configured to generate the permeability enhancing substance in vivo.

4. The device of claim 1 , wherein the permeability enhancer-dispensing portion and the drug-dispensing portion are configured to respectively dispense the permeability enhancing substance and the at least one drug into the lumen through separate nozzles.

5. The device of claim 1 , wherein the actuator comprises a piston.

6. The device of claim 1 , wherein the permeability enhancing substance comprises hydrogen peroxide.

7. The device of claim 1 , wherein the permeability enhancing substance is stored in a first repository and the at least one drug is stored in a second repository separate from the permeability enhancing substance.

8. The device of claim 1 , wherein the at least one drug comprises a protein or peptide.

9. The device of claim 1 , wherein the at least one drug comprises a hormone or steroid.

10. The device of claim 1 , wherein the control module is adapted to receive at least one of power and control signals from a transmitting device when the device is deployed in the lumen.

11. The device of claim 1 , wherein the control module is configured to sequence dispensing of the at least one drug from the drug-dispensing portion and release or generation of the permeability enhancing substance from the permeability enhancer-dispensing portion.

12. The device of claim 1 , wherein the permeability enhancing substance comprises a chemical enhancer selected from the group consisting of DMSO, hydrogen peroxide, propylene glycol, oleic acid, cetyl alcohol, benzalkonium chloride, sodium lauryl sulphate, isopropyl myristate, Tween 80, dimethyl sulfoxide, dimethyl formamide, dimethyl acetamide, sodium lauroylsarcosinate, sorbitan monolaurate, methylsulfonylmethane, Azone, terpenes, phosphatidylcholine dependent phospholipase C, triacyl glycerol hydrolase, acid phosphatase, phospholipase A2, a concentrated saline solution, and a combination thereof.

13. The device of claim 1 , wherein the permeability enhancing substance comprises an enzyme inhibitor selected from the group consisting of protease inhibitors, antiretrovirals, diisopropylfluorophosphate (DFP), α-difluoromethylornithine (DFMO), trypanothione reductase, methotrexate, allopurinol, acyclovir, and a combination thereof.

14. The device of claim 1 , wherein the permeability enhancer-dispensing portion comprises an actuator configured to actively dispense the permeability enhancing substance from the housing by positive displacement, the actuator comprising a mechanical displacement element, an osmotic swelling displacement element, a gas-volume displacement element, a magnetically-induced phase transformation element, a thermally-induced phase transformation element, a piezoelectric actuator, an electrostatically-induced compression element, and an actuatable dispensing valve with a static pressure head.

15. The device of claim 1 , further comprising:
a first dispensing nozzle, the drug-dispensing portion configured to dispense the at least one drug from the housing through the first dispensing nozzle; and
a second dispensing nozzle, the permeability enhancer-dispensing portion configured to dispense the permeability enhancing substance from the housing through the second dispensing nozzle.

16. The device of claim 15 , wherein the control module is configured to independently control a timing and sequence of delivery of the at least one drug through the first nozzle and a timing and sequence of delivery of the permeability enhancing substance through the second nozzle.

17. The device of claim 1 , wherein the drug-dispensing portion and the permeability enhancer-dispensing portion are configured to respectively dispense the at least one drug and the permeability enhancing substance into the lumen along an axial direction of the housing.

18. A method for transmucosal drug delivery comprising:
deploying and retaining a drug delivery device within a lumen of a human or animal subject, the device comprising a housing shaped and dimensioned for intralumenal deployment into, retention in, and removal from the lumen of a human or animal subject;
dispensing at least one drug from a drug-dispensing portion which contains the at least one drug and comprises an actuator, dispensing the at least one drug from the housing causing the actuator to dispense the at least one drug through the housing by positive displacement;
releasing a permeability enhancing substance from a permeability enhancer dispensing portion of the drug delivery device, the permeability enhancing substance disrupting at least one region of a mucosal barrier of the lumen adjacent to the housing by inhibiting enzyme activity or rendering the mucosal barrier more permeable to the at least one drug at a selected time while intralumenally deployed and retained in the lumen of the human or animal subject; and
controlling, by a control module contained in the housing, the releasing or generating of the permeability enhancing substance and the dispensing of the at least one drug by activation of the actuator;
wherein the dispensing of the at least one drug includes dispensing the at least one drug from the housing to the at least one region of the mucosal barrier disrupted by the permeability enhancing substance.

19. The method of claim 18 , further comprising removing the drug delivery device from the lumen after dispensing the at least one drug.

20. The method of claim 18 , further comprising controlling the dispensing of the at least one drug independently from controlling the releasing of the permeability enhancing substance.

21. The method of claim 18 , wherein dispensing the at least one drug from the drug-dispensing portion comprises dispensing the at least one drug into the lumen along an axial direction of the housing.

22. The method of claim 18 , further comprising receiving at least one of power and control signals from a transmitting device when the drug delivery device is deployed in the lumen.

23. The method of claim 18 , further comprising generating the permeabi

Assignees

• Palo Alto Res Ct Inc

Inventors

• Uhland Scott
• Peeters Eric
• Fatakdawala Hussain

Classifications

• A61M31/002 Primary

  Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time (artificial gland structures or devices A61F2/022; intra-uterine contraceptive devices A61F6/14; tampons for introducing into the vagina A61F13/20, A61L15/00; suppositories or bougies for intra-vaginal or intra-uterine application A61K9/02; physical forms of medicinal preparations for sustained or differential drug release A61K9/20, A61K9/50) · CPC title

• A61K9/0036

  Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms · CPC title

• A61M2210/1475

  Vagina · CPC title